Novocure announces organizational changes

Novocure announced organizational changes to prepare for future growth, effective Jan. 17. Pritesh Shah, Novocure’s Chief Commercial Officer, will transition into a new executive role as Chief Growth Officer. In this role, Shah will have worldwide responsibilities for product and portfolio strategy, brand management, establishing a global framework for new launches, market access and market intelligence. Shah will also be responsible for new indications in the United States. After a review of Novocure’s future needs, Ely Benaim, M.D., Chief Medical Officer, will step down from his role and leave the company. Dr. Benaim will partner with Novocure’s executive leadership team to ensure a smooth transition of responsibilities. Piet Hinoul, M.D., Ph.D., currently Senior Vice President & Head of Global Medical Affairs, will assume the role of interim Head of Medical to ensure business continuity as the company continues its external search for the next Chief Medical Officer. Dr. Hinoul will report to Shah while Novocure concludes its executive search. Uri Weinberg, M.D., Ph.D., currently Chief Science Officer, will transition into a new role as Chief Innovation Officer. In this role, Dr. Weinberg will be responsible for expanding the innovative potential of Tumor Treating Fields therapy. Moshe Giladi, Ph.D., currently Senior Vice President, Preclinical Research, will assume the role of Chief Science Officer at Novocure.